Lantulos

Quick links to important sections

Lantulos

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lantulos

Property Description
Active ingredient Lactulose (INN)
Form Oral Solution or Syrup
Pharmacological class Osmotic Laxative, Ammonia Reducer
Origin Synthetic disaccharide
Prescription Status Typically Prescription-Only (Rx)

What is Lantulos and its Core Identity?

Lantulos is a liquid pharmaceutical preparation whose active component is Lactulose, a type of non-absorbable sugar. It is supplied as an oral solution or syrup, classified as an osmotic laxative and also recognized for its function as an ammonia reducer. The medicine is typically designated as a Prescription-Only medication in many jurisdictions, which confirms its use in conditions requiring professional management.

Its identity is fundamentally that of a hyperosmotic agent, meaning its primary mechanism involves drawing water into the lower bowel. Pharmacological studies clinically recognize its efficacy for regulating bowel function, especially in cases of impaired motility. The preparation is administered via the oral route, ensuring the Lactulose is delivered efficiently for its targeted action.

Composition and Primary Actions

The active compound, Lactulose, is a synthetic disaccharide chemically manufactured from the simple sugars fructose and galactose. Lantulos is formulated as a single-ingredient product, containing only Lactulose dissolved in an aqueous solution base. This synthetic entity possesses a molecular structure that is poorly absorbed by the human small intestine, concentrating its activity within the colon.

Its general purpose is two-fold: to assist in regulating bowel function and to aid the body with specific internal waste elimination. The osmotic laxative effect promotes softer stools and facilitates easier evacuation. Furthermore, its crucial action as an ammonia reducer helps assist in the removal of excess nitrogenous waste from the bloodstream, a specialized function distinguishing it within the class of gastrointestinal agents.

Regulatory References

  1. Lactulose - StatPearls (NIH/NCBI Bookshelf)

What side effects are possible with Lantulos?

Possible Side Effects and Safety Information

The safety profile of Lantulos (Lactulose) is organized by regulatory authorities based on observed frequency, system-organ class, and specific safety considerations. Most documented adverse reactions relate to the gastrointestinal system.

Adverse Reactions and Frequency Classification

Adverse reactions are classified according to frequency, based on clinical data and post-marketing reports, as documented in official prescribing information:

  • Very Common (Affecting 1 in 10 or more): Flatulence, Abdominal pain.
  • Common (Affecting up to 1 in 10): Nausea, Vomiting, Diarrhea (at standard doses).
  • Uncommon (Affecting up to 1 in 100): Electrolyte imbalance, Hypernatraemia (high sodium level).

Safety-Related Restrictions and Considerations

The product label outlines specific high-level restrictions on use (contraindications), including Gastro-intestinal obstruction, Galactosaemia, and any risk of perforation in the digestive tract. These restrictions are mandated by regulatory agencies to address known safety risks.

Time-related patterns indicate that flatulence often resolves spontaneously after the first few days of treatment. Conversely, the occurrence of diarrhea may signal that the dosage is too high.

Serious safety concerns documented in regulatory materials involve the potential for severe electrolyte disturbance and dehydration. These risks are associated with excessive or prolonged fluid loss resulting from high-dose use that causes persistent diarrhea or vomiting. For special populations, the label specifies that use in children should be exceptional and subject to medical supervision. Similarly, older adults receiving high doses should be monitored for signs of electrolyte imbalance.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Lantulos

The official regulatory profile for Lantulos overdosage focuses strictly on managing documented clinical and physiological outcomes.


Documented Manifestations and Risks

Feature Official Regulatory Statement
Documented Manifestations: Overdosage primarily results in diarrhea and abdominal cramps; abdominal pain may also occur.
Physiological Risks: The critical risk is the excessive loss of fluids and electrolytes, potentially leading to imbalances such as hypokalemia and hypernatremia.
Population Notes: Elderly and debilitated patients may require periodic monitoring of serum electrolytes. Infants are at risk for dehydration and hyponatremia.

Required Emergency Actions

Official guidance mandates that the medication should be terminated or the dose immediately reduced upon recognizing symptoms of overdosage. Urgent medical help is required because treatment is entirely symptomatic and supportive, as no specific pharmacological antidote is documented in the official prescribing information. Medical procedures must focus on initiating fluid and electrolyte replacement to correct the documented disturbances and prevent serious systemic consequences. The severity is defined by the need to correct the loss of essential electrolytes.

Therapeutic Uses of Lantulos

What Lantulos Treats: Main Uses and Benefits

Support for Chronic Constipation and Bowel Function

Lantulos is commonly used to relieve symptom clusters related to physical discomfort and strain associated with chronic constipation, including the passing of hard, dry stools and infrequent bowel movements. It is relevant when supportive symptom management is appropriate, as it supports patients during difficult episodes by easing distress and assists with maintaining functional stability. This contributes to improved day-to-day comfort during symptomatic periods.

“This medication is applied in situations involving certain distressing symptoms where assistance with maintaining functional stability is needed.”

Quick Fact: Addressing Hard Stool Symptoms Lantulos is primarily applied in scenarios where symptoms interfere with daily functioning, contributing to easing the overall symptom load related to hard, dry stools, a common manifestation of persistent bowel irregularity.


Management of Hepatic Encephalopathy Symptoms

The medication is also applied across domains where additional symptomatic support is needed for Hepatic Encephalopathy (HE), a condition marked by symptoms related to systemic imbalance such as confusion and altered mental status. Lantulos is commonly used for managing acute episodes and is considered relevant for easing symptoms that may become disruptive during flare-ups. This provides support that helps ease the overall symptom load and assists with maintaining functional stability for patients with chronic liver impairment.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Lantus (insulin glargine) is intended for use in adults with diabetes mellitus and pediatric patients (children and adolescents) with Type 1 diabetes. Official eligibility and non-eligibility are defined by specific regulatory categories:


Contraindicated Populations

The medicine must not be used in patients experiencing an episode of hypoglycemia (low blood sugar) or in those with a known hypersensitivity (allergy) to insulin glargine or any of the formulation's inactive ingredients (excipients).

Restricted and Conditional Use

  • Acute Condition: The medicine is not recommended for the treatment of diabetic ketoacidosis (DKA).
  • Organ Function: Patients with renal (kidney) or hepatic (liver) impairment may require a reduction in the required dose due to changes in insulin metabolism, necessitating careful medical monitoring.
  • Age: While generally approved for children, use has not been established for children under 2 years of age in some official labels, or under 6 years of age in others.
  • Pregnancy/Lactation: The medicine can be used during pregnancy, if clinically needed. Careful monitoring and dose adjustments are essential. Use during breastfeeding is considered acceptable, though dose adjustments may be required.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lantulos (Lactulose) exhibits a specific interaction profile due to its minimal systemic absorption and local action within the colon. Regulatory information primarily documents pharmacodynamic interactions and certain chemical and procedural restrictions.


Pharmacodynamic and Electrolyte Interactions

Co-administration of non-absorbable antacids may interfere with the primary therapeutic action of Lantulos by inhibiting the required drop in colonic pH. This effect may lead to a reduced therapeutic response. Concurrent use of Lantulos with other laxatives may result in an additive laxative effect, which can complicate the assessment of treatment adequacy.


Risk of Hypokalemia Reinforcement

The potential for hypokalemia (low serum potassium) caused by excessive, prolonged, or dose-related diarrhea from Lantulos is reinforced by co-administration with potassium-losing agents, such as thiazide diuretics or steroids. This potential for hypokalemia, as officially documented, may in turn increase the toxicity risk associated with cardiac glycosides (e.g., Digoxin).


Formal Restrictions and Procedural Constraints

The medication is contraindicated in patients who require a low-galactose diet due to the presence of trace sugars in the solution. For patients undergoing electrocautery procedures during proctoscopy or colonoscopy, thorough bowel cleansing with a non-fermentable solution is required beforehand to mitigate a documented theoretical hazard from gas accumulation. A specific timing separation is noted, where the co-administration of Lanthanum Carbonate should be separated from Lantulos by at least two hours. Use is noted with caution in diabetic patients due to the content of trace sugars.

Mechanism of Action

The pharmacological action of the active ingredient, Lactulose, is entirely dependent on its delivery to the colon and subsequent interaction with the native microbial flora. This mechanism produces a dual physiological consequence involving changes in fluid dynamics and nitrogen partitioning.

Microbial Fermentation and Osmotic Hydration

Lactulose functions as a non-absorbable substrate for saccharolytic colonic microbiota. This microbial breakdown produces Short-Chain Fatty Acids (SCFAs) and simultaneously creates a hyperosmotic load within the colon. This cascade results in water being drawn into the lumen, increasing the volume of colonic contents and altering the consistency of the colonic contents. The SCFAs physically stimulate peristalsis (smooth muscle contraction), which subsequently reduces the transit time of colonic contents.

Chemical Modulation and Nitrogen Iontrapping

The SCFAs produced during fermentation are responsible for a crucial drop in the colonic mathrmpH. This acidic environment chemically modulates the lipid-soluble ammonia (mathrmNH3) absorbed from the gut by converting it into the non-absorbable ammonium ion (mathrmNH4^+), a process called iontrapping. The resulting trapped mathrmNH4^+ is prevented from diffusing back into the bloodstream, which reduces the quantity of mathrmNH3 available for systemic absorption from the gut.

Dosage and Administration Information

How to Use Lantulos

Lantulos (Lactulose) is administered primarily as an oral solution or syrup, although a powder formulation is also available. For acute management of Hepatic Encephalopathy (HE), the medication has an approved specialized use via the rectal route as a retention enema.

Dosing and Frequency

The fundamental principle governing the use of Lantulos is dose titration, meaning the amount taken is adjusted to meet a specific physiological endpoint rather than a fixed schedule.

Indication Standard Oral Dosing Regimen Frequency Pattern
Chronic Constipation Typically 15 mL to 30 mL (10 g to 20 g) daily. May be increased to 60 mL if necessary. Once daily, or split into two divided doses.
Hepatic Encephalopathy (HE) Initial dose is 30 mL to 45 mL (20 g to 30 g). Maintenance dose is adjusted to produce two to three soft stools per day. Three or four times daily during the acute initial phase.

Administration Requirements

The prescribed dose should be measured using a calibrated measuring device provided with the product. To enhance palatability, the dose may be mixed with water, fruit juice, or milk. When taking a single daily dose, it is generally recommended to consume the dose at the same time each day. Patients are also advised to maintain sufficient daily fluid intake during therapy.

Use Over Time and Special Considerations

The onset of the medication's intended effect can take 24 to 48 hours as it must reach the colon to work. While use for constipation may be short-term, HE management often involves continuous long-term therapy to prevent recurrence. Dosing rules for children and infants must be determined by a healthcare professional, though specific ranges are established for these populations.

Recent Clinical Evidence

Research evidence / Overview of studies for Lantulos

The research available for Lantulos was evaluated in studies for two primary conditions. The available research, consisting mainly of randomized controlled trials (RCTs) and comprehensive reviews, studies help show what has been observed so far in specific patient groups.


Evidence for use in Chronic Constipation (CC)

Research has explored how symptoms change over time in patients with chronic constipation. The core evidence for this indication was evaluated in short-term RCTs that primarily focused on patient-reported outcomes describing perceived discomfort and outcomes monitoring physiological strain.

Studies monitored outcomes related to physical discomfort, such as infrequent bowel movements and stool consistency. Data show patterns related to how the outcomes evolved in the observed populations during the study period. Findings describe patterns observed in the studies of adults who received this compound for short observation periods.

However, the certainty regarding long-term management remains low based on the available trial structures. The follow-up durations were limited, focusing on acute changes rather than durability of effects over many months. Additionally, evidence quality varies across studies, and some research highlights a lack of methodologically high-quality trials for managing this condition.


Evidence for use in Hepatic Encephalopathy (HE)

For Hepatic Encephalopathy (HE), the research base was evaluated in a higher volume of studies, including many large systematic reviews and meta-analyses. This research examined temporary physiological imbalance related to conditions involving periods of heightened symptoms.

The studies explored two critical axes: outcomes describing episodic or acute changes in clinical status and outcomes related to systemic or functional imbalance (monitoring blood ammonia levels). Findings help contextualize how patients reported their experience, as trials monitored how symptoms evolved during research conducted during periods of increased symptom activity. Research highlights measurements data show patterns related to a reduction in blood ammonia concentration.

When used for prophylaxis, or prevention, studies monitored recurrence patterns and outcomes reflecting daily functioning in high-risk groups with underlying liver disease over defined time intervals.


Long-term Studies and Follow-up Duration

Studies have varied significantly in their follow-up duration depending on the condition being studied. For constipation, the evidence is largely focused on short-term data and acute symptomatic relief.

Conversely, research scenarios related to Hepatic Encephalopathy prophylaxis have included intermediate to long-term observation periods, sometimes extending up to a year or more to track recurrence patterns. However, even in these longer studies, long-term effects are not fully established outside of the specific study protocols, and data for certain groups remain insufficient for outcomes related to sustained daily functioning.


Research in Special Populations

The initial clinical evaluation for chronic constipation primarily included adults and geriatric patients. Research has explored its use in pediatric populations for constipation, although subgroup findings are uncertain and this evidence is limited.

For Hepatic Encephalopathy, studies focused on Adult patients with cirrhosis across different severity strata of the condition. This includes populations with minimal/covert HE as well as those with acute manifestations of the systemic imbalance.


What is Still Uncertain About Lantulos Research

Research provides context but not individual predictions. A key limitation for the HE indication is that ethical constraints have prevented the initiation of new placebo-controlled RCTs for acute, overt cases. In this area, evidence may be influenced by reliance on findings from trials conducted several decades ago.

For both conditions, comparative evidence is lacking against all currently available treatment options, and the methodological quality of available evidence varies across studies. For HE, outcomes capturing phases of heightened symptom activity, such as patient-reported outcomes describing perceived discomfort and quality of life, are considered of very low certainty. Evidence highlights what is known — and what is still uncertain — about this medicine.

Key Studies & References

  1. Lactulose: MedlinePlus Drug Information (NIH/NLM)
  2. Lactulose: StatPearls [Internet] (NIH/NCBI Bookshelf)
  3. Review of the Efficacy of Lactulose for the Management of Chronic Constipation
  4. Guideline for the Evaluation and Management of Chronic Constipation in the Elderly

Frequently Asked Questions (FAQ)

Common questions about Lantulos (FAQ)

Q: Is Lantulos a type of 'long-acting' or 'basal' medication?

A: Lantulos is not typically classified using terms like 'long-acting' or 'basal,' which are generally reserved for injectable medicines. However, official information indicates its action is prolonged because it is poorly absorbed and must reach the colon to be broken down by bacteria, a process that can take 24 to 48 hours to produce the intended effect.

Q: Is it common to have skin irritation where Lantulos is used?

A: According to the official product information, the most commonly documented side effects are related to the digestive system, such as gas, abdominal pain, nausea, and diarrhea. Other reactions affecting the skin, such as a rash or hives, have also been reported but are not documented as common or very common.

Q: What happens if I forget to use Lantulos one day?

A: Regulatory guidance suggests that if a dose is missed, it can be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose is skipped entirely. Official documents state that a double dose should not be taken to make up for a missed one.

Q: Is it safe to use Lantulos if I have a kidney condition?

A: Official documents state that due to negligible systemic absorption, no special dosage recommendations exist for patients with kidney impairment. However, due to the potential for electrolyte imbalance resulting from diarrhea, caution is described in the product information.

Q: Can Lantulos interact with over-the-counter supplements like vitamins?

A: No known problems have been documented regarding the mixing of Lantulos with general vitamins or herbal supplements. However, it is important to inform a healthcare provider of all the medicines and supplements being used.

Q: Is there a generic version of Lantulos available?

A: Yes, the active ingredient in Lantulos is Lactulose. Official marketing documents indicate that Lactulose oral solution is widely available as a generic formulation, in addition to being available under various brand names.

Q: Can children or teenagers use Lantulos?

A: The use and dosage for children must be determined by a healthcare provider. Some regulatory documents state that use in younger children, especially for treating Hepatic Encephalopathy, has not been established. For general use in constipation, official guidance suggests that use in children under 14 should occur only when recommended by a doctor.

Q: How should Lantulos affect my blood sugar level overnight?

A: Because Lantulos is poorly absorbed into the body, it is generally considered to have a minimal impact on blood glucose levels when taken at standard doses. However, the official product information advises caution for all diabetic patients due to the presence of trace sugars, such as galactose and lactose.

Q: What are the risks if Lantulos is used during pregnancy?

A: Official labeling states that use during pregnancy is advised only when clearly needed, following determination by a healthcare provider. Research indicates animal studies have not shown evidence of harm to the fetus; however, there are no adequate, controlled studies in pregnant women.

Q: What are the requirements for storing and traveling with Lantulos?

A: Official labeling states that Lantulos should be stored at controlled room temperature, typically around 20 C to 25 C. The solution must be protected from freezing. General travel advice suggests keeping the medicine with you and avoiding storage in places with extreme heat or cold.

Q: Are the side effects of Lantulos the same for everyone?

A: No, the official product information classifies side effects based on how often they occur in the study population (e.g., 'Very Common' affects more than 1 in 10 people). This classification system confirms that not every patient will experience the same side effects.

Q: Is a headache a common side effect when starting Lantulos?

A: Headache is not listed among the very common or common side effects that are documented in the official product information for Lantulos.

Q: What is the difference between Lantulos and a rapid-acting insulin?

A: Lantulos is Lactulose, a synthetic sugar that belongs to the class of osmotic laxatives and ammonia reducers. It is functionally and chemically distinct from rapid-acting insulin, which is a protein hormone used to manage blood sugar levels throughout the body.

Q: Can Lantulos be prescribed for people who do not have diabetes?

A: Yes, the approved uses for Lantulos are the treatment of chronic constipation and hepatic encephalopathy. Neither of these conditions requires a patient to have a diagnosis of diabetes.

Q: Is it safe for a breastfeeding mother to use Lantulos?

A: Official guidance indicates that use during breastfeeding is considered acceptable; however, caution is advised by regulators. This is because the drug is poorly absorbed and unlikely to reach the infant, but it is not definitively known whether the drug is excreted in human milk.

Q: Do people typically experience hypoglycemia (low blood sugar) while using Lantulos?

A: Low blood sugar, or hypoglycemia, is not listed among the very common, common, or uncommon side effects documented for Lantulos in the official product information.

Q: Are there specific groups where Lantulos has been studied less?

A: Yes, research limitations are documented. Ethical constraints have prevented the initiation of new placebo-controlled randomized trials for acute Hepatic Encephalopathy. Furthermore, evidence regarding the use of Lantulos in pediatric groups for treating constipation is often noted as limited or uncertain.

Q: Is it normal to feel tired when first starting Lantulos?

A: Tiredness is not listed as a common side effect of the drug itself. However, official safety information indicates that unusual tiredness or weakness may be a symptom of a serious, although uncommon, adverse reaction, such as dehydration or electrolyte imbalance, and should be reported to a healthcare provider.

Q: Does Lantulos have specific warnings for people with heart problems?

A: An official warning exists regarding patients taking certain heart medications known as cardiac glycosides (e.g., Digoxin). This is because the risk of electrolyte imbalance (hypokalemia) caused by diarrhea can potentially increase the toxicity of those heart medications.

Q: Can Lantulos be used if a person has certain liver issues?

A: Lantulos is indicated for treating Hepatic Encephalopathy, which is a severe liver complication. For general liver impairment not related to HE, regulatory documents state that no special dose adjustment is usually needed due to the drug’s negligible systemic absorption.

Q: Do I need to change my diet when I start using Lantulos?

A: The only strict dietary restriction is for patients who require a low-galactose diet due to a medical condition called Galactosaemia. For other patients, official guidance notes the importance of maintaining sufficient daily fluid intake during therapy.

Q: Can Lantulos be used by people who have Type 1 diabetes?

A: Official product information advises caution for all diabetic patients, regardless of the type of diabetes, due to the presence of trace sugars (galactose and lactose) in the solution. This is a point that should be reviewed with a healthcare provider.

Q: Does Lantulos cause any issues with my stomach or digestion?

A: Yes, the primary function of Lantulos is to promote easier bowel movements by changing the digestive contents in the colon. Consequently, its most commonly reported side effects are related to the gastrointestinal system, including gas (flatulence), abdominal pain, nausea, and diarrhea.

Q: What kind of medical professional typically prescribes Lantulos?

A: Lantulos is a Prescription-Only medicine (Rx), meaning it must be prescribed by a licensed healthcare provider. This may include general practitioners or specialists like gastroenterologists and hepatologists, who often manage the conditions the medicine is used to treat.

Q: What data do studies provide regarding the duration of Lantulos's effect?

A: Official information states that the onset of the intended effect can take 24 to 48 hours. The duration of its local action is related to the time it takes for the drug to be fully metabolized by the bacteria in the colon, which is generally complete at standard doses.

Q: What are common patient misunderstandings about how Lantulos works?

A: One common point of patient clarification is the distinction between the active ingredient, Lactulose, and Lactose (milk sugar). Lantulos is Lactulose, a synthetic sugar that is poorly absorbed, which is different from how the body handles Lactose.

How should Lantulos be stored and disposed of?

Official Storage and Disposal Requirements

Storage instructions for Lantus (insulin glargine) differ based on whether the product is unopened or in use.

Storage Conditions

State Temperature Range Time Limit
Unopened (Vial or Pen) Refrigerated (2 C to 8 C) Until Expiration Date
In Use (Vial or Pen) Room Temperature (Below 30 C/86 F) Discard after 28 days

Protection and Handling

The medication must be protected from freezing; discard it if it has been frozen. Do not store the pen with the needle attached after use. Lantus must also be protected from direct heat and light. Keep the unopened product in the original outer carton.

Disposal

All used needles and other sharps must be disposed of in a specialized, puncture-proof sharps container according to federal and local regulations. The medicine and all injection materials should be kept out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lantulos found in:

A-Z Index: